Cryptophycin 1 - CAS 124689-65-2

Cryptophycin 1 - CAS 124689-65-2 Catalog number: BADC-00569

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Cryptophycin 1, produced by Nostoc sp. GSV 224, is a potent cytotoxic anti-microtubule agent. Cryptophycin 1 can induce cell apoptosis, and has anti-tumor activity and excellent anti-proliferation ability.

Category
ADCs Cytotoxin
Product Name
Cryptophycin 1
CAS
124689-65-2
Catalog Number
BADC-00569
Molecular Formula
C35H43ClN2O8
Molecular Weight
655.19
Purity
≥95%
Cryptophycin 1

Ordering Information

Catalog Number Size Price Quantity
BADC-00569 -- $-- Inquiry
Description
Cryptophycin 1, produced by Nostoc sp. GSV 224, is a potent cytotoxic anti-microtubule agent. Cryptophycin 1 can induce cell apoptosis, and has anti-tumor activity and excellent anti-proliferation ability.
Synonyms
Cryptophycin A; Cryptophycin; Cyclo[(2R)-2-methyl-β-alanyl-(2S)-2-hydroxy-4-methylpentanoyl-(2E,5S,6S)-5-hydroxy-6-[(2R,3R)-3-phenyl-2-oxiranyl]-2-heptenoyl-3-chloro-O-methyl-D-tyrosyl]; 1,4-Dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone, 10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiranyl]ethyl]-, (3S,6R,10R,13E,16S)-; (3S,6R,10R,13E,16S)-10-(3-Chloro-4-methoxybenzyl)-3-isobutyl-6-methyl-16-{(1S)-1-[(2R,3R)-3-phenyl-2-oxiranyl]ethyl}-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone
IUPAC Name
(3S,6R,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone
Canonical SMILES
CC1CNC(=O)C(NC(=O)C=CCC(OC(=O)C(OC1=O)CC(C)C)C(C)C2C(O2)C3=CC=CC=C3)CC4=CC(=C(C=C4)OC)Cl
InChI
InChI=1S/C35H43ClN2O8/c1-20(2)16-29-35(42)44-27(22(4)31-32(46-31)24-10-7-6-8-11-24)12-9-13-30(39)38-26(33(40)37-19-21(3)34(41)45-29)18-23-14-15-28(43-5)25(36)17-23/h6-11,13-15,17,20-22,26-27,29,31-32H,12,16,18-19H2,1-5H3,(H,37,40)(H,38,39)/b13-9+/t21-,22+,26-,27+,29+,31-,32-/m1/s1
InChIKey
PSNOPSMXOBPNNV-VVCTWANISA-N
Density
1.171±0.1 g/cm3
Solubility
Soluble in Methanol
Appearance
White or Light Colored Glassy Solid
Shipping
Room temperature
Boiling Point
889.4±65.0°C at 760 mmHg
In Vitro
Cryptophycin reduced the in vitro polymerization of bovine brain microtubules by 50% at a drug:tubulin ratio of 0.1. Cryptophycin did not alter the critical concentration of tubulin required for polymerization, but instead caused substoichiometric reductions in the amount of tubulin that was competent for assembly. Consistent with its persistent effects on intact cells, cryptophycin-treated microtubule protein remained polymerization-defective even after cryptophycin was reduced to sub-inhibitory concentrations. The effects of cryptophycin were not due to denaturation of tubulin and were associated with the accumulation of rings of microtubule protein. The site of cryptophycin interaction with tubulin was examined using functional and competitive binding assays. Cryptophycin blocked the formation of vinblastine-tubulin paracrystals in intact cells and suppressed vinblastine-induced tubulin aggregation in vitro. Cryptophycin inhibited the binding of [3H]vinblastine and the hydrolysis of [gamma32P]GTP by isolated tubulin, but did not block the binding of colchicine.
In Vivo
The cryptophycin analogue LY355703 is a potent inhibitor of microtubule polymerization that displays in vitro and in vivo activity in cell lines and tumor xenografts displaying the multidrug-resistant phenotype. In a Phase I trial, 25 patients received LY355703 as a 2-h i.v. infusion on day 1 and day 8 repeated every 3 weeks. Doses were escalated from 0.1 to 2.22 mg/m2 using a modified continual reassessment method. Neurological toxicity was found to be dose-limiting at 1.84 and 2.22 mg/m2. Among four patients treated at these doses, two had grade 4 constipation/ileus, one with severe myalgias, and one had grade 3 motor neuropathy. These findings were reversible. The 1.5 mg/m2 dose level was well tolerated. An amended twice-weekly schedule was pursued in 11 patients in an attempt to improve dose intensity and avoid dose-limiting neurotoxicity. Doses of >0.75 mg/m2 on a day 1, 4, 8, and 11 schedule every 21 days were not tolerated as a result of nausea/constipation, suggesting that LY335703 toxicity is not schedule dependent and is related to cumulative dose.
1.Cryptophycin-39 Unit A Precursor Synthesis by a Tandem Shi Epoxidation and Lactonization Reaction of trans-Styryl Acetic Acid
Benedikt Sammet, Hanna Radzey, Beate Neumann, Hans-Georg Stammler, Norbert Sewald
Unit A of cryptophycins is a delta-hydroxy acid with two or four stereogenic centers. The first synthesis of the unit A building block of cryptophycin-39 is based on a catalytic asymmetric Shi epoxidation of trans-styryl acetic acid followed by an in situ lactonization. The scope of this reaction has been investigated with respect to various beta,gamma-unsaturated carboxylic acids as substrates for the asymmetric synthesis of 4-hydroxy-5-phenyl-tetrahydrofuran-2-ones under Shi conditions.
2.Synthetic routes towards cryptophycin unit A diastereomers
Eissler, Stefan; Neumann, Beate; Stammler, Hans-Georg; Sewald, Norbert
Unit A of cryptophycin 1 is a delta-hydroxy acid with four stereogenic centres. Our unit A synthesis introduces the first two stereogenic centres by a catalytic, asymmetric dihydroxylation, whereas the remaining two stereogenic centres are established by diastereoselective reactions. In this letter, we focus on the diastereoselectivity of these reactions and discuss the accessibility of cryptophycin unit A diastereomers.
3.The Synthesis of Cryptophycins
Stefan Eissler, Arvydas Stoncius, Markus Nahrwold, Norbert Sewald
Nature provides a huge reservoir of highly diverse chemical compounds with interesting biological properties. Secondary metabolites continue to represent promising candidates for therapeutic applications and drugs are very often based on natural pro­ducts. Frequently, the total synthesis of such compounds is a real challenge, and this also drives the development of new synthetic methodology. This review article focuses on the biochemistry and chemistry of cryptophycins, a class of 16-membered macrocyclic depsipeptides. The first representative was isolated more than 15 years ago from cyanobacteria. With respect to structure, the class can be subdivided into two structural categories, containing either an epoxide or an alkene moiety. The bioactivity of cryptophycins is based on their ability to interact with tubulin. They display considerable tumour-selective cytotoxicity both against multidrug-resistant tumour cell lines and solid tumours implanted in mice. Consequently, cryptophycin derivatives are considered as potential antitumour drugs. Despite the fact that the cryptophycins were discovered only recently, several different synthetic approaches have already been published. In addition to information on the synthesis of the subunits A-D, strategies for both their assembly and the macrocyclisation are compiled in this review.
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Historical Records: Cryptophycin 1
Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Resources & Supports
Inquiry Basket